Christopher Halliday joins DLA Piper’s Patent Prosecution practice and Life Sciences sector in Philadelphia
DLA Piper announced today that Christopher Halliday has joined the firm’s Patent Prosecution practice and Life Sciences sector as a partner in Philadelphia.
In his practice, Halliday counsels clients on strategic intellectual property issues in the pharmaceutical, biotechnology, chemical, medical device and food science areas. He prepares and prosecutes patent applications related to new chemical entities, pharmaceutical formulations and biologics, as well as implantable medical devices, chemical processes and catalysts.
“Chris’s addition will enhance our patent prosecution capabilities in the Philadelphia market and across our global platform,” said Larissa Bifano, US chair of DLA Piper’s Patent Prosecution practice. “His skillset and established history of handling the complex intellectual property issues that arise in mergers and acquisitions, as well as his experience negotiating licenses, transfer agreements and assignments, will also be beneficial to our clients, particularly those in the life sciences industry.”
“Chris brings a strong background in biochemistry and chemical engineering that will significantly expand our ability to support life sciences sector clients in both transactional and litigation work,” added Andrew Gilbert, global co-chair of the firm’s Life Sciences sector.
Halliday joins from Morgan Lewis and Bockius. He received his JD and LLM in intellectual property from the University of New Hampshire’s Franklin Pierce School of Law, his LLM in trial advocacy from Temple University’s Beasley School of Law, and his BS in chemical engineering and BS in biochemistry from Penn State University.